Jenn Abelin, Ph.D.

Jenn Abelin is a senior group leader in the Proteomics Platform at the Broad Institute of MIT and Harvard and an affiliated researcher of Dana-Farber Cancer Institute’s Translational Immunogenomics Lab (TIGL). Abelin leads a multi-disciplinary team of researchers who work closely with their collaborators to develop and apply mass spectrometry-based immunopeptidomics to identify peptides displayed to T cells by HLA-I and HLA-II cell surface molecules, which play a major role in adaptive immune responses. Immunopeptidomics enables a deeper understanding of antigen processing and presentation and allows the direct identification of disease specific HLA-I and HLA-II bound peptides, which are potential therapeutic targets.

Prior to rejoining the Broad Institute at the end of 2019, Abelin established and led the immunopeptidomics group at the biotech Neon Therapeutics from 2016 to 2019. From 2013 to 2016, Abelin was a postdoctoral fellow in the Proteomics Platform. She is also a recipient of a Merkin Institute Fellowship at the Broad in 2025.

Abelin received her B.Sc. from Guilford College in biology and chemistry (2009) and her Ph.D. from the University of Virginia (2012).